GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer | Version 2.0 What does an LDL-C of 80 mg/dL tell you? Two patients return with the same LDL-C. One started at 200 mg/dL, the other at 100 mg/dL. The updated analyzer puts the untreated value back in view and
Tag: ApoB
Beyond LDL-C: Understanding Cardiovascular Risk With PREVENT, ApoB, Lp(a), Non-HDL-C and Advanced Lipid Analysis
GlobalRPh Clinical TechnologyBeyond LDL-C: Understanding Cardiovascular Risk With PREVENT, ApoB, Lp(a), Non-HDL-C and Advanced Lipid AnalysisIntroducing the GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer, a layered cardiovascular prevention tool that combines the standard lipid panel with advanced lipoprotein markers, derived calculations, kidney and metabolic context, coronary calcium, and the American
Insulin Resistance in Non-Obese Patients: The “Metabolically Obese Normal Weight” Paradox
Insulin Resistance in Non-Obese Patients: The "Metabolically Obese Normal Weight” Paradox Review Abstract Normal body mass index (BMI) has long been used as a convenient and widely accepted screening tool for assessing overweight, obesity, and cardiometabolic risk. Although BMI remains valuable for population level surveillance and initial clinical
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden
The Rise of Precision Lipidology: Beyond LDL-C to ApoB, Lp(a), and Atherogenic Particle Burden Review Abstract Lipidology is undergoing a clinically important transition from traditional cholesterol-centered assessment toward a more precise evaluation of atherogenic lipoprotein burden. Low-density lipoprotein cholesterol (LDL-C) remains a validated therapeutic target
